Neutrophil elastase inhibitor prevents endotoxin-induced liver injury following experimental partial hepatectomy (Br J Surg 2007; 94: 609–619)

2007 ◽  
Vol 94 (7) ◽  
pp. 911-911
Author(s):  
T. Fujita
Keyword(s):  
Liver Injury ◽  
Partial Hepatectomy ◽  
Neutrophil Elastase ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor

Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706

1999 ◽  
Vol 66 (5) ◽  
pp. 501-508 ◽  
Author(s):  
F KOIZUMI ◽  
M MURAKAMI ◽  
H KAGEYAMA ◽  
M KATASHIMA ◽  
M TERAKAWA ◽  
...  
Keyword(s):  
Neutrophil Elastase ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor

Study on Perioperative Administration of a Neutrophil Elastase Inhibitor for Interstitial Pneumonias

2017 ◽  
Vol 103 (6) ◽  
pp. 1781-1787 ◽  
Author(s):  
Mariko Fukui ◽  
Kazuya Takamochi ◽  
Shiaki Oh ◽  
Takeshi Matsunaga ◽  
Kazuhiro Suzuki ◽  
...  
Keyword(s):  
Neutrophil Elastase ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor

scholarly journals Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice

2017 ◽  
Author(s):  
Hironori Mikumo ◽  
Toyoshi Yanagihara ◽  
Naoki Hamada ◽  
Eiji Harada ◽  
Saiko Ogata-Suetsugu ◽  
...  
Keyword(s):  
Neutrophil Elastase ◽  
Therapeutic Agent ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Lavage Fluid ◽  
Egfr Mutations ◽  
Airway Epithelial ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor ◽  
Promising Therapeutic Agent

ABSTRACTBackground and objectiveGefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is an effective therapeutic agent for non-small cell lung cancer with EGFR mutations. It can cause severe acute pneumonitis in some patients. We previously demonstrated that mice with naphthalene-induced airway epithelial injury developed severe gefitinib-induced pneumonitis and that neutrophils played important roles in the development of the disease. This study aimed to investigate the effects of the neutrophil elastase inhibitor sivelestat on gefitinib-induced pneumonitis in mice.MethodsC57BL/6J mice received naphthalene (200 mg/kg) intraperitoneally on day 0. Gefitinib (250 or 300 mg/kg) was orally administered to mice from day −1 until day 13. Sivelestat (150 mg/kg) was administered intraperitoneally from day 1 until day 13. Bronchoalveolar lavage fluid (BALF) and lung tissues were sampled on day 14.ResultsSivelestat treatment significantly reduced the protein level, neutrophil count, neutrophil elastase activity in BALF, and severity of histopathologic findings on day 14 for mice administered with 250 mg/kg of gefitinib. Moreover, sivelestat treatment significantly improved the survival of mice administered with 300 mg/kg of gefitinib. Conclusions: These results indicate that sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.Summary statementNeutrophil elastase inhibitor sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.

Protection Against Acute Lung Injury by Intravenous or Intratracheal Pretreatment with EPI-HNE-4, a New Potent Neutrophil Elastase Inhibitor

2002 ◽  
Vol 26 (3) ◽  
pp. 290-297 ◽  
Author(s):  
Christophe Delacourt ◽  
Sabine Hérigault ◽  
Christophe Delclaux ◽  
Alain Poncin ◽  
Micheline Levame ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Neutrophil Elastase ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document